Answers are grounded in this paper and cite their sources.
STAPHYLOCOCCUS aureusis one of the most common causes of both hospital- and community-acquired infections worldwide, and the antimicrobial agent vancomycin has been used to treat manyS. aureusinfections, particularly those caused by methicillinresistantS. aureus(MRSA). In 1996, the first documented case of infection caused by a strain ofS. aureuswith intermediate levels of resistance to vancomycin (VISA; minimum inhibitory concentration [MIC]=8 μg/mL) was reported from Japan.¹This report describes the first isolation of VISA from a patient in the United States, which may be an early warning thatS. aureusstrains with full resistance to vancomycin will emerge. In July 1997, VISA-associated peritonitis was diagnosed in a patient who was being treated with long-term ambulatory peritoneal dialysis. During January 1996-June 1997, the patient had been treated with multiple courses of both intraperitoneal and intravenous vancomycin for repeated episodes of MRSA-associated peritonitis. The
No takes yet. Share an insight, caveat, or question.
A 1997 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: